Multiple system atrophy (MSA) is an adult-onset, rapidly progressive neurodegenerative disorder characterised by the aggregation of α-synuclein in oligodendroglial cytoplasmatic inclusions.1 ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale -- Effects seen on both daily function ...
Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency AskBio Inc. (AskBio), a ...
Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple System Atrophy pipeline constitutes 20+ key companies continuously working towards developing ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity” or 'the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...
- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a ...
Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
This was a single-arm, interventional-, single-center, open-label prospective study. Patients with a history of probable MSA [15] were enrolled in the study (Table 1). All patients had some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results